ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. ContraFect Corporation has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. The company also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
http://www.priceseries.com/trade/CFRX-ContraFect-Corp-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2022020420220303.html
Related Posts :
TCMD Tactile Systems Technology Inc gains 29% Jun 4, 2018Tactile Systems Technology, Inc., a medical technology company, develops and provides med… 
NOG Northern Oil and Gas, Inc. gains 46% Jun 4, 2018Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, ex… 
SHOS Sears Hometown and Outlet Stores, Inc. gains 16% Jun 4, 2018Sears Hometown and Outlet Stores, Inc. engages in the retail sale of home appliances, law… 
SCYX SCYNEXIS, Inc. gains 29% Jun 4, 2018SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives t… 
MRTX Mirati Therapeutics, Inc. gains 19% Jun 4, 2018Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipelin…
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments